Positioning no disclosures inside 60 days, left as found
Options put/call open interest 6.13, read 2026-11-02
Ethical does not pass the values gate
Price15.65 USD
Fair value18.26
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-09-24Read Accumulation15.10+3.6% to today ✓Markup gives way to Accumulation after a 61% rise in 12 weeks
2026-07-02Read Markup9.39+66.7% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Avantor, Inc. holds its Markdown at $15.65. Consolidating, no directional conviction, held for 45 days.
As held on the ledger · 2026-11-04
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 45 days
Price at the screen
$15.65
Valuation
31.30 trailing · 17.64 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.95
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
33.46%
Below 33%
Interest-bearing debt is 33.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
12.21%
Below 49%
Money owed to the company is 12.2% of assets, under the 49% limit.
Pass
Revenue purity
0.64%
Below 5%
Only 0.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Avantor,'s business is in a permissible area, but its interest-bearing debt is about 33% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AVTR's ethical verdict changes
Today AVTR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 14% discount to our $18.26 fair value, 4.60% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 14.3% discount to the base estimate.
Where our models see it going: fair-value estimate $18.26, with a range of $14.63 to $24.39, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Lab suppliers face flat sales and red ink
Every time a scientist reaches for a reagent or a factory lines up solvents, Avantor sits in the middle of the chain. Yet the firm posts zero revenue growth, an 8% negative profit margin and negative 9% return on equity. Shares sit 18% above our fair value estimate and the consensus target from sixteen analysts is only $10, so we pass.
The ethical screen clears, which removes one layer of concern. Still the forward price-to-earnings multiple of 13 times offers no margin for the lack of growth or the unknown competitive position.
Risk sits in the combination of thin demand and weak returns that could linger if biopharma spending stays subdued. Currency moves and customer concentration add further pressure. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AVTR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Accumulation$15.59-6.2%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (14 analysts) rates it hold, with a mean price target of $10.
2026-10-28Accumulation$16.62+0.0%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (14 analysts) rates it hold, with a mean price target of $10. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$16.62+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (14 analysts) rates it hold, with a mean price target of $10. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$16.62+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (14 analysts) rates it hold, with a mean price target of $10. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$16.62+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 44% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (14 analysts) rates it hold, with a mean price target of $10. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$16.62+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 44% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (14 analysts) rates it hold, with a mean price target of $10. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$16.62+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 44% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (14 analysts) rates it hold, with a mean price target of $10. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$16.62+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 44% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (14 analysts) rates it hold, with a mean price target of $10. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$16.62+3.3%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 44% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (14 analysts) rates it hold, with a mean price target of $10. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Accumulation$16.09+2.7%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 44% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (14 analysts) rates it hold, with a mean price target of $10.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
